Celularity Stock Discussion

$Celularity (CELU.US)$ $ReShape Lifesciences (RSLS.US)$ $Zooz Power (ZOOZ.US)$ $Prestige Wealth (PWM.US)$ $BioVie (BIVI.US)$ $Cyclacel Pharmaceuticals (CYCC.US)$ $Processa Pharmaceuticals (PCSA.US)$ $GRI Bio (GRI.US)$ $Spirit Airlines (SAVE.US)$ $Expion360 (XPON.US)$ $VSee Health (VSEE.US)$
📊⚡️📊

$Edesa Biotech (EDSA.US)$ $Caravelle International (HTCO.US)$ $Intrusion (INTZ.US)$ $SRM Entertainment (SRM.US)$ $Calidi Biotherapeutics (CLDI.US)$ $Visionary Holdings (GV.US)$ $Boqii (BQ.US)$ $Celularity (CELU.US)$ $Zooz Power (ZOOZ.US)$ $GRI Bio (GRI.US)$ $Expion360 (XPON.US)$ $Spirit Airlines (SAVE.US)$ $VSee Health (VSEE.US)$
📊⚡️📊

$Celularity (CELU.US)$
17/10/2024 - 05:15
FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it had added to its commercial portfolio of placental-derived advanced biomaterial products with the acquisition of Rebound, a full thickness placental-d...

$Celularity (CELU.US)$ Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

FLORHAM PARK, N.J., October 16, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it had added to its commercial portfolio of placental-derived advanced biomaterial products with the acquisition of Rebound, a full thickness placent...

$Celularity (CELU.US)$ Celularity Presents Data On T-Cell Therapy Platform At ASCO Annual Meeting; PT-CD16VS Shows Potent Activity And Potential For Combination With Monoclonal Antibodies To Target Multiple Cancers

$Celularity (CELU.US)$ Celularity Granted European Patent EP3957315 For Treatment Of Diabetic Peripheral Neuropathy Using Placental Cells

$Celularity (CELU.US)$
NEWS
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
Celularity (NASDAQ: CELU) has announced that data published in the Journal for ImmunoTherapy of Cancer highlights the benefits of its placental-derived T-Cell platform for CAR-T therapies. The study revealed that CAR-T cells from Celularity's platform demonstrated greater persistence, resistance to exhaustion, and efficacy compared to tho...

$Celularity (CELU.US)$ Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
Benzinga· 2 mins ago

$Celularity (CELU.US)$ Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L
Benzinga· 1 min ago

$Annovis Bio (ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...